Literature DB >> 27186421

MiR-654-5p attenuates breast cancer progression by targeting EPSTI1.

Yu-Yan Tan1, Xiao-Yun Xu2, Jin-Feng Wang3, Cheng-Wu Zhang3, Sheng-Chu Zhang3.   

Abstract

MicroRNAs (miRNAs) dysregulation is a common event in a variety of human diseases including breast cancer. However, clinical relevance and biological role of miR-654-5p in the progression of breast cancer remain greatly elusive. Herein, the expression levels of miR-654-5p were aberrantly downregulated in human breast cancer specimens and four breast cancer cell lines. Low expression of miR-654-5p was strongly associated with advanced TNM stage and lymph node metastasis as well as a poor survival. Functional analysis showed that miR-654-5p overexpression inhibited cell growth and invasion, and induced cell apoptosis in two aggressive breast cancer cells. Further studies demonstrated that Epithelial stromal interaction 1 (EPSTI1) was a direct target gene of miR-654-5p and showed an inverse correlation with miR-654-5p expression. Forced expression of EPSTI1 could abrogate the inhibitory effect of miR-654-5p on the growth and invasion of breast cancer cells as well as apoptosis-induced ability. In conclusion, the present study highlights that miR-654-5p acts as a tumor suppressor in breast cancer through directly targeting EPSTI1, and their functional regulation may open a novel avenue with regard to the therapeutic target for breast cancer.

Entities:  

Keywords:  EPSTI1; breast cancer; miR-654-5p; miRNA; survival

Year:  2016        PMID: 27186421      PMCID: PMC4859678     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  25 in total

Review 1.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 2.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

3.  Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.

Authors:  Päivi Östling; Suvi-Katri Leivonen; Anna Aakula; Pekka Kohonen; Rami Mäkelä; Zandra Hagman; Anders Edsjö; Sara Kangaspeska; Henrik Edgren; Daniel Nicorici; Anders Bjartell; Yvonne Ceder; Merja Perälä; Olli Kallioniemi
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

4.  Identification of EPSTI1, a novel gene induced by epithelial-stromal interaction in human breast cancer.

Authors:  Helga Lind Nielsen; Lone Rønnov-Jessen; René Villadsen; Ole W Petersen
Journal:  Genomics       Date:  2002-05       Impact factor: 5.736

5.  MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions.

Authors:  Girish C Shukla; Jagjit Singh; Sailen Barik
Journal:  Mol Cell Pharmacol       Date:  2011

6.  Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

Authors:  Volkmar Müller; Stephan Gade; Bettina Steinbach; Sibylle Loibl; Gunter von Minckwitz; Michael Untch; Kathrin Schwedler; Kristina Lübbe; Christian Schem; Peter A Fasching; Christine Mau; Klaus Pantel; Heidi Schwarzenbach
Journal:  Breast Cancer Res Treat       Date:  2014-08-03       Impact factor: 4.872

Review 7.  Metastatic breast cancer: the treatment challenge.

Authors:  Stephen E Jones
Journal:  Clin Breast Cancer       Date:  2008-06       Impact factor: 3.225

8.  Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up.

Authors:  Athina Markou; George M Yousef; Efstathios Stathopoulos; Vassilis Georgoulias; Evi Lianidou
Journal:  Clin Chem       Date:  2013-10-16       Impact factor: 8.327

Review 9.  Origins of metastatic traits.

Authors:  Sakari Vanharanta; Joan Massagué
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

10.  MiR-630 suppresses breast cancer progression by targeting metadherin.

Authors:  Ci-Xiang Zhou; Chen-Long Wang; An-Lu Yu; Qiu-Yu Wang; Meng-Na Zhan; Jun Tang; Xiu-Feng Gong; Qian-Qian Yin; Ming He; Jian-Rong He; Guo-Qiang Chen; Qian Zhao
Journal:  Oncotarget       Date:  2016-01-12
View more
  16 in total

1.  LPS induces HUVEC angiogenesis in vitro through miR-146a-mediated TGF-β1 inhibition.

Authors:  Yize Li; Huayu Zhu; Xu Wei; Heng Li; Zhicao Yu; Hongmei Zhang; Wenchao Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Authors:  Blanca Majem; Alfonso Parrilla; Carlos Jiménez; Leticia Suárez-Cabrera; Marta Barber; Andrea Marín; Josep Castellví; Gabriel Tamayo; Gema Moreno-Bueno; Jordi Ponce; Xavier Matias-Guiu; Francesc Alameda; Ignacio Romero; José Luis Sánchez; Asunción Pérez-Benavente; Sebastián Moran; Manel Esteller; Jaume Reventós; Marina Rigau; Antonio Gil-Moreno; Miguel F Segura; Anna Santamaría
Journal:  Oncogene       Date:  2019-07-05       Impact factor: 9.867

3.  EPSTI1 promotes monocyte adhesion to endothelial cells in vitro via upregulating VCAM-1 and ICAM-1 expression.

Authors:  Yan-Rou Bei; Shun-Chi Zhang; Yu Song; Mao-Lin Tang; Ke-Lan Zhang; Min Jiang; Run-Chao He; Shao-Guo Wu; Xue-Hui Liu; Li-Mei Wu; Xiao-Yan Dai; Yan-Wei Hu
Journal:  Acta Pharmacol Sin       Date:  2022-07-01       Impact factor: 6.150

4.  miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1.

Authors:  Guinv Hu; Xiaokang Zhao; Jiang Wang; Liting Lv; Chaoqun Wang; Liang Feng; Liangqiong Shen; Weili Ren
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

5.  Gelsolin inhibits malignant phenotype of glioblastoma and is regulated by miR-654-5p and miR-450b-5p.

Authors:  Jiakang Zhang; Takuya Furuta; Hemragul Sabit; Sho Tamai; Shabierjiang Jiapaer; Yu Dong; Masashi Kinoshita; Yasuo Uchida; Sumio Ohtsuki; Tetsuya Terasaki; Shiguang Zhao; Mitsutoshi Nakada
Journal:  Cancer Sci       Date:  2020-05-29       Impact factor: 6.716

6.  Screening of Recurrence Related MicroRNA in Ductal Carcinoma In Situ and Functional Study of MicroRNA-654-5p.

Authors:  Shi Li; Tianjie Pu; Lin Xiao; Hongwei Gao; Li Li; Feng Ye; Yueping Liu; Hong Bu
Journal:  J Breast Cancer       Date:  2019-01-02       Impact factor: 3.588

7.  miR-496, miR-1185, miR-654, miR-3183 and miR-495 are downregulated in colorectal cancer cells and have putative roles in the mTOR pathway.

Authors:  Naif Alqurashi; Saeed M Hashimi; Faisal Alowaidi; Saso Ivanovski; Amro Farag; Ming Q Wei
Journal:  Oncol Lett       Date:  2019-06-21       Impact factor: 2.967

8.  miR-654-5p Targets HAX-1 to Regulate the Malignancy Behaviors of Colorectal Cancer Cells.

Authors:  Fuda Huang; Xianjian Wu; Mingwei Wei; Houji Guo; Hua Li; Zesheng Shao; Yi Wu; Jian Pu
Journal:  Biomed Res Int       Date:  2020-02-10       Impact factor: 3.411

9.  Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.

Authors:  Yujuan Lu; Jingzhi Zhang; Yanhui Wu
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

10.  Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1.

Authors:  Yina Qiao; Ting Jin; Shengdong Guan; Shaojie Cheng; Siyang Wen; Huan Zeng; Maojia Zhao; Liping Yang; Xueying Wan; Yuxiang Qiu; Qiao Li; Manran Liu; Yixuan Hou
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.